Decoy Therapeutics Inc. (formerly Salarius Pharmaceuticals) will begin trading under the ticker symbol DCOY on January 8, 2026. The company’s focus is on developing peptide-conjugate therapeutics using AI technology to streamline drug development. Their 2026 plan includes advancing an antiviral into clinical trials and expanding their pipeline and partnerships. Decoy is also working on programs targeting respiratory viruses and GI cancers, with a lead antiviral program attracting interest from global health organizations. The company aims to achieve multiple value-creating milestones in 2026 and is open to strategic partnerships and non-dilutive funding opportunities.

Read more at GlobeNewswire: Salarius Pharmaceuticals Changes Corporate Name to Decoy